THE CLINICAL TRIAL
The primary objective of the Dahlias Study was to assess the efficacy and safety of an IV drug designed to lower the levels of autoantibodies circulating in the bloodstream and ease symptoms for adults with Primary Sjogren’s Syndrome (PSS). Primary Sjögren’s Syndrome is an autoimmune disorder characterized by the body’s immune system attacking its own moisture-producing glands, leading to dryness in the mouth and eyes. PSS can significantly impact individuals by causing chronic dryness of the mouth and eyes, which can lead to difficulties in speaking, swallowing, and increased risk of dental decay and eye infections.
THE PROJECT
Dahlias’ clinical team needed assistance with patient recruitment and retention for their clinical trial that included eleven countries and multiple languages. To achieve this, the team collaborated with Stark / Raving Health to create a suite of patient and site facing materials that promoted study enrollment and facilitated study participation.